Dongbang FTL was founded in 1990 with the corporate philosophy of "contributing to the happiness and health of mankind with the highest quality pharmaceuticals."
Over the past 30 years, we have expanded our business from synthetic APIs(Active Pharmaceutical Ingredients) to natural APIs, health functional foods, and finished pharmaceutical products. And we have proven our ability to produce the highest quality pharmaceuticals through certifications such as EU-GMP (France ANSM), Japan GMP (PDMA), and Australia GMP (TGA).
Currently, based on the technology accumulated so far, we are focusing on providing CMC(Chemistry, Manufacturing and Controls) and CDMO(Contract Development and Manufacturing Organization) services to various global bio/pharma companies, startups, and research institutes.
Furthermore, we are securing and expanding a number of first-in-class drugs and best-in-class drug pipelines by expanding our investment in new drug development for the future.
In 2022, for the supply of COVID-19 treatments in the world's middle and low-income countries, the United Nations-affiliated International Pharmaceutical Patent Pool (MPP) granted only certain companies around the world the authority to produce generic APIs for Pfizer's Paxlovid (component name Nirmatrelvir·Ritonavir) and MSD's Lagebrio (component name Molnupiravir), and Dongbang FTL was qualified to produce generic APIs for both treatments. This was another opportunity to realize the corporate ideology of "contributing to human health" rather than the benefit of the company while demonstrating our technology.
We will grow into a company that presents and leads the future of the Bio Pharma Industry.
